Merck Total Assets 2010-2023 | MRK

Merck total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Merck total assets for the quarter ending December 31, 2023 were $106.727B, a 0.33% decline year-over-year.
  • Merck total assets for 2022 were $109.16B, a 3.28% increase from 2021.
  • Merck total assets for 2021 were $105.694B, a 15.4% increase from 2020.
  • Merck total assets for 2020 were $91.588B, a 8.52% increase from 2019.
Merck Annual Total Assets
(Millions of US $)
2022 $109,160
2021 $105,694
2020 $91,588
2019 $84,397
2018 $82,637
2017 $87,872
2016 $95,377
2015 $101,677
2014 $98,167
2013 $105,645
2012 $106,132
2011 $105,128
2010 $105,781
2009 $112,314
Merck Quarterly Total Assets
(Millions of US $)
2023-09-30 $106,727
2023-06-30 $104,469
2023-03-31 $107,796
2022-12-31 $109,160
2022-09-30 $107,081
2022-06-30 $107,095
2022-03-31 $106,668
2021-12-31 $105,694
2021-09-30 $93,494
2021-06-30 $90,688
2021-03-31 $90,847
2020-12-31 $91,588
2020-09-30 $89,800
2020-06-30 $90,615
2020-03-31 $84,913
2019-12-31 $84,397
2019-09-30 $83,331
2019-06-30 $83,965
2019-03-31 $82,354
2018-12-31 $82,637
2018-09-30 $85,130
2018-06-30 $85,040
2018-03-31 $86,041
2017-12-31 $87,872
2017-09-30 $91,676
2017-06-30 $92,804
2017-03-31 $96,561
2016-12-31 $95,377
2016-09-30 $98,335
2016-06-30 $96,475
2016-03-31 $98,755
2015-12-31 $101,677
2015-09-30 $101,232
2015-06-30 $102,582
2015-03-31 $108,345
2014-12-31 $98,167
2014-09-30 $101,808
2014-06-30 $97,860
2014-03-31 $108,460
2013-12-31 $105,645
2013-09-30 $106,419
2013-06-30 $106,876
2013-03-31 $106,200
2012-12-31 $106,132
2012-09-30 $106,301
2012-06-30 $105,525
2012-03-31 $105,509
2011-12-31 $105,128
2011-09-30 $106,534
2011-06-30 $106,195
2011-03-31 $105,865
2010-12-31 $105,781
2010-09-30 $107,840
2010-06-30 $106,171
2010-03-31 $111,594
2009-12-31 $112,314
2009-09-30 $48,739
2009-06-30 $49,407
2009-03-31 $46,543
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $321.544B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $743.143B 123.75
Novo Nordisk (NVO) Denmark $557.486B 45.93
Johnson & Johnson (JNJ) United States $390.509B 15.54
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Pfizer (PFE) United States $150.148B 14.53
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80